<DOC>
	<DOCNO>NCT01109004</DOCNO>
	<brief_summary>The study design Phase III , multicenter trial tandem autologous transplant plus maintenance therapy versus strategy single autologous transplant plus consolidation therapy lenalidomide , bortezomib dexamethasone ( RVD ) follow maintenance therapy single autologous transplant plus maintenance therapy part upfront treatment multiple myeloma ( MM ) . Lenalidomide use maintenance therapy three year arm .</brief_summary>
	<brief_title>Stem Cell Transplant With Lenalidomide Maintenance Patients With Multiple Myeloma ( BMT CTN 0702 )</brief_title>
	<detailed_description>The primary objective randomize trial compare three-year progression-free survival ( PFS ) three treatment arm pairwise comparison . Mobilization therapy specify study . Randomization three treatment arm do prior first transplant . All patient undergo first autologous peripheral blood stem cell ( PBSC ) transplant high-dose melphalan ( 200 mg/m^2 IV ) give Day -2 . Upon recovery first transplant patient receive either second autologous PBSC transplant condition regimen first transplant consolidation therapy RVD ( lenalidomide 15 mg/day Days 1-14 , dexamethasone 40 mg Days 1 , 8 15 , bortezomib 1.3mg/m^2 Days 1 , 4 , 8 11 every 21 day cycle , patient receive four cycle ) maintenance lenalidomide ( 15 mg daily ) . All patient also receive maintenance lenalidomide start second transplant , first autologous transplant consolidation therapy depend treatment arm . Maintenance therapy lenalidomide start 10 mg daily three month increase 15 mg daily . The duration maintenance three year treatment arm .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients meet criterion symptomatic multiple myeloma ( MM ) . Patients 70 year age , young , time enrollment . Patients receive least two cycle regimen initial systemic therapy within 2 12 month first dose initial therapy . Cardiac function : leave ventricular ejection fraction rest great 40 percent . Hepatic : bilirubin le 1.5x upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less 2.5x upper limit normal . ( Patients diagnose Gilbert 's Disease allow exceed define bilirubin value 1.5x upper limit normal . ) Renal : Creatinine clearance grater equal 40 mL/min , estimate calculate . Pulmonary : Diffusing capacity lung carbon monoxide ( DLCO ) , forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) great 50 percent predict value ( correct hemoglobin ) . Patients adequate autologous graft define cryopreserved PBSC graft contain great equal 4 x 10^6 CD34+ cells/kg patient weight . The graft may CD34+ select otherwise manipulate remove tumor cell . The graft collect transplant institution refer center . The autograft must store two product contain least 2 x 10^6 CD34+ cells/kg patient weight . Signed informed consent form . Patients never fulfill criterion symptomatic MM . Patients purely nonsecretory MM [ absence monoclonal protein ( M protein ) serum measure electrophoresis immunofixation absence Bence Jones protein urine define use conventional electrophoresis immunofixation technique ] . Patients light chain MM detect serum free light chain assay eligible . Patients plasma cell leukemia . Karnofsky performance score le 70 percent . Patients great grade 2 sensory neuropathy ( CTCAE ) . Patients uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) . Patients seropositive human immunodeficiency virus ( HIV ) . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity bortezomib , boron mannitol . Patient receive investigational drug 14 day enrollment . Patients prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent le 5 year previously allow unless approve Protocol Officer one Protocol Chairs . Cancer treat curative intent great 5 year previously allow . Female patient pregnant ( positive BHCG ) breastfeeding . Females childbearing potential ( FCBP ) men sexual contact FCBP unwilling use contraceptive technique length lenalidomide maintenance therapy . Prior allograft prior autograft . Patients receive midintensity melphalan ( great 50 mg IV ) part prior therapy . Patients unable unwilling provide inform consent . Prior organ transplant require immunosuppressive therapy . Patients disease progression prior enrollment . Patients receive lenalidomide initial therapy MM experience toxicity result treatment discontinuation . Patients experience thromboembolic event full anticoagulation prior therapy lenalidomide thalidomide . Patients unwilling take deep vein thrombosis ( DVT ) prophylaxis . Patients undergo intervention treatment arm due priori denial medical cost coverage third party payer . Patients unable unwilling return transplant center assign treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Symptomatic Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Anti-Myeloma Agents</keyword>
	<keyword>Hematologic Disorders</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Progression</keyword>
	<keyword>Autologous Transplant</keyword>
	<keyword>RVD Consolidation</keyword>
</DOC>